Novarx Corporation
Records under this name other than patents Novarx Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Novarx Corporation
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,101,543 | Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells Term ended Term ended Nov 2, 2022 · USPTO record | Term ended | Term ended Nov 2, 2022 | USPTO record |
| US 7,740,837 | Genetically modified cells expressing a TGF beta inhibitor, the cells being lung cancer cells Term ended Term ended Nov 22, 2021 · USPTO record | Term ended | Term ended Nov 22, 2021 | USPTO record |
| US 8,293,252 | Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization Lapsed on the fee record Ended Oct 23, 2020 · USPTO record | Lapsed on the fee record | Ended Oct 23, 2020 | USPTO record |
| US 6,120,763 | Compositions and methods for enhanced tumor cell immunity in vivo Term ended Term ended Nov 12, 2017 · USPTO record | Term ended | Term ended Nov 12, 2017 | USPTO record |
| US 6,447,769 | Compositions and methods for enhanced tumor cell immunity in vivo Term ended Ended no later than Jul 18, 2014 · USPTO record | Term ended | Ended no later than Jul 18, 2014 | USPTO record |
| US 8,444,964 | Compositions and methods for enhanced tumor cell immunity in vivo Term ended Ended no later than Jul 18, 2014 · USPTO record | Term ended | Ended no later than Jul 18, 2014 | USPTO record |
| US 5,772,995 | Compositions and methods for enhanced tumor cell immunity in vivo Term ended Term ended no later than Jun 30, 2018 · Low confidence | Term ended | Term ended no later than Jun 30, 2018 | Low confidence |